Tiagabine for Rage, Aggression, and Anxiety

Abstract

Back to table of contents Previous article Next article LetterFull AccessTiagabine for Rage, Aggression, and AnxietyDaniel A. Hoffman, M.D., Daniel A. HoffmanSearch for more papers by this author, M.D., Medical Director,Neuro-Therapy Clinic,Denver, COPublished Online:1 May 2005AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail SIR: Few studies have examined the effects of pharmacologic augmentation in patients with treatment-resistant rage and aggression. Gamma-aminobutyric acid (GABA) may be critical in the neurochemical control of aggressive behavior.1 Agents that modulate GABA-ergic activity have been shown to significantly reduce aggressive symptoms.1Management of behavioral complications of psychiatric disorders, such as rage and aggression, presents a clinical challenge. When faced with patients who continue to exhibit these symptoms, despite otherwise adequate treatment, clinicians will often augment therapy, rather than switch medications. However, few studies have examined the effects of pharmacologic augmentation in patients with treatment-resistant rage and aggression.Gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter, may be critical in the neurochemical control of aggressive behavior.1 Agents that modulate GABA-ergic activity, including valproic acid, topiramate, and gabapentin, have been shown to significantly reduce aggressive symptoms.1Tiagabine, a selective GABA reuptake inhibitor (SGRI), increases synaptic GABA availability via transporter inhibition.2 Preliminary reports suggest that tiagabine may be effective in the treatment of a variety of anxiety disorders, including generalized anxiety disorder in an open-label study and posttraumatic stress disorder (PTSD) and panic disorder (PD) in case-series reports.3–5We conducted a retrospective chart review of 36 consecutive patients (aged 15–54 years), with symptoms of rage, aggression, or anxiety in association with one or more of the following disorders: bipolar, intermittent explosive, major depression, PD, attention deficit hyperactivity disorder, or substance abuse. All patients had previously tried a variety of medications (including antidepressants, anxiolytics, antipsychotics, anticonvulsants, mood stabilizers, and central nervous system stimulants), yet they continued to display excessive anxiety, anger, rage, abuse, or irritability. In addition to existing treatment regimens, patients initially received tiagabine 4 mg/day (2 mg bid) and then were titrated on an individual basis. Treatment response was graded by the physician using a 4-point categorical scale (none, minimal, good, or excellent). A patient with a rating of “good” or “excellent” was defined as a responder.Twenty-nine patients were eligible for analysis; the remaining seven patients were lost to follow up or were noncompliant. Of these, 20 patients (69%) demonstrated a good or excellent response to tiagabine (responder), with reduction or elimination of the symptoms of rage, aggression, or anxiety. Symptomatic improvement was noted as early as 2 weeks after initiating treatment, and sustained for a period of up to 52 weeks. Tiagabine dosage ranged from 4 to 32 mg/day (dosed hs, bid, tid, or qid), with 75% of responders receiving doses ≤16 mg/day, taken mainly bid. One patient discontinued due to lack of efficacy. Tiagabine treatment was well tolerated. Of the 29 patients, 8 discontinued treatment because of the following adverse events: cognitive dysfunction (N=4) and acne, depression, fatigue, and panic attacks (N=1 for each).These preliminary findings indicate that tiagabine augmentation may be effective in reducing the symptoms of rage, aggression, and anxiety. Further evaluation in controlled clinical trials is warranted.References1 Kim E: The use of newer anticonvulsants in neuropsychiatric disorders. Curr Psychiatry Rep 2002; 4:331–337Crossref, Medline, Google Scholar2 Fink-Jensen A, Suzdak PD, Swedberg MD, et al: The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur JGoogle Scholar3 Schwartz TL: The use of tiagabine augmentation for treatment resistant anxiety disorders: A case series. Psychopharmacol Bull 2002; 36:53–57Medline, Google Scholar4 Berigan T: Treatment of posttraumatic stress disorder with tiagabine. Can J Psychiatry 2002; 47:7887Google Scholar5 Zwanzger P, Baghai TC, Schule C, et al: Tiagabine improves panic and agoraphobia in panic disorder patients (letter). J Clin Psychiatry 2001; 62:656–657Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited ByInfluence of glutamate and GABA transport on brain excitatory/inhibitory balance7 February 2021 | Experimental Biology and Medicine, Vol. 246, No. 9Review of toxicity and trends in the use of tiagabine as reported to US poison centers from 2000 to 201229 March 2015 | Human & Experimental Toxicology, Vol. 35, No. 2Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior5 July 2011 | Journal of Psychopharmacology, Vol. 26, No. 7Chinese Journal of Chemistry, Vol. 30, No. 1Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Vol. 91Discovering imaging endophenotypes for major depression23 May 2011 | Molecular Psychiatry, Vol. 16, No. 6Chromatographia, Vol. 70, No. 7-8Effects of acute tiagabine administration on aggressive responses of adult male parolees21 January 2008 | Journal of Psychopharmacology, Vol. 22, No. 2The Consultant Pharmacist, Vol. 22, No. 12Treating persistent adolescent aggressionCurrent Treatment Options in Neurology, Vol. 8, No. 5Pharmacoepidemiology and Drug Safety, Vol. 14, No. 12 Volume 17Issue 2 May 2005Pages 252-252 Metrics PDF download History Published online 1 May 2005 Published in print 1 May 2005